EREG and cancer: As EREG is subject to frequent mutation, amplification and deep deletion as suggested by the TCGA pan-cancer atlas studies which document global genomics data (Fig. 7h and Supplementary Fig. 9f), this factor has been considered an important predictor of disease progression in treatment-naïve patients of multiple cancer types [49–51].